0.5 Gy confers resistance to a subsequent high dose of γ-rays by modulating HO-1/Nrf2 and apoptosis pathways.

0.5 Gy 的辐射剂量通过调节 HO-1/Nrf2 和细胞凋亡通路,赋予细胞对后续高剂量 γ 射线的抵抗力

阅读:8
作者:Ali Yasser F, Hassan Ibrahim M, Abdelhafez Hussein M, Desouky Omar S
Ionizing radiation, from the DNA centric view, elicits biological effects and health consequences solely through energy deposition events in the cell nucleus. At higher radiation doses, this is likely true; however, at low doses, non-targeted effects, a subcategory of which is the adaptive response, tend to dominate. Controversies exist over the definition of low dose. From a radiation therapy view, it is defined as 0.5-0.7 Gy. Therefore, we investigated the effects of exposure to ionizing radiation with or without a 0.5 Gy priming dose. Techniques including comet assay, flow cytometry, fluorescence microscopy, and real-time quantitative PCR were employed. In normal lung fibroblasts (WI-38), there was a statistically significant difference in mean normalized tail moments when comparing treatment with the challenge dose alone to treatment with a 0.5 Gy priming dose prior to the challenge dose (P < 0.05). Moreover, pretreatment with a 0.5 Gy priming dose reduced G1 phase cell cycle arrest and cell death-either through apoptosis or mitotic catastrophe-induced by the subsequent 2 Gy exposure. Similarly, A549 Cells pre-exposed to a 0.5 Gy priming dose before a 2 Gy exposure showed a lower percentage of apoptosis than those exposed to the 2 Gy alone. Mechanistically, cells responded to a priming 0.5 Gy by increasing the expression of HMOX1, SOD, and Bcl2 while decreasing of IL-1β and TNF-α. In conclusion, 0.5 Gy induces an adaptive response in lung normal and cancer cell against subsequent high doses of γ-rays. Modulation of the HO-1/Nrf2 and apoptosis pathways underlie the resistance observed in primed cells.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。